An Early Phase 1 interventional study of Aspirin in Preeclampsia Possible, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by NYU Langone Health · Early Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing aspirin in Pre-Eclampsia — 18 open to participants now, 22 under way, 5 of them phase 3. Aspirin · Pre-Eclampsia.
Among the 52 studies testing aspirin in Pre-Eclampsia, this one is the 48th largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 14 of the 21 other live ones, and was the 50th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →18 of the 52 studies testing aspirin in Pre-Eclampsia are open now, in 11 countries. Recruiting first, the newest first:
University of Calgary · Sites in Belgium, Canada, Denmark and 4 more countries
Ages 18+ · Women only
Medicare Hospital (Pvt) Limited · Sites in Pakistan
Ages 18–45 · Women only
Thomas Jefferson University · Sites in United States
Ages 16–55 · Women only
Ohio State University · Sites in United States
Ages 14–35 · Women only
University of Pennsylvania · Sites in United States
Ages 18–45 · Women only
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 13 · Phase 4 16
First in 2001; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 235 across the 52 interventional studies. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 52 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 2 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
6 of the studies testing aspirin in Pre-Eclampsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05924971MemorialCare Health SystemAspirin for Postpartum Patients With Preeclampsia | 2026-12 |
| NCT04479072University of ChicagoAspirin and Preeclampsia | 2026-12-01 |
| NCT07373756Dr. Sunita PunRandomized Controlled Study to Compare Efficacy of Aspirin 75mg and 150mg In the Prevention of Preeclampsia In High Risk Pregnant Women | 2026-12-31 |
| NCT06281665Malamo CountourisTreatment With Aspirin After Preeclampsia: TAP Trial | 2027-01-01 |
| NCT07041385Shalamar HospitalComparing the Efficacy of 75mg Versus 150mg Aspirin for the Prevention of Preeclampsia in High-Risk Pregnant Women | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 52 studies testing aspirin in Pre-Eclampsia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.
Drug: Aspirin
81mg twice a day (162mg total)
Also known as: Acetylsalicylic acid
Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in serum thromboxane
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in complete blood count
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Mean Platelet Volume (MPV)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Platelet Distribution Width (PDW)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Plateletcrit (PCT)
Time frame: Baseline, 4 weeks after initiation of aspirin
Change in Life's Essential 8 questionnaire
Life's Essential 8 (LE8) is a cardiovascular health scoring system from the American Heart Association that rates health from 0 to 100 based on diet, activity, smoking, sleep, BMI, cholesterol, blood sugar, and blood pressure. Scores indicate high cardiovascular health, 50-79 is moderate, and below 50 is low. A score of 100 is ideal, while 0 represents the lowest health condition, such as severe, uncontrolled risk factors.
Time frame: Baseline, 4 weeks after initiation of aspirin
Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: lucia.muzzarelli@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to lucia.muzzarelli@nyulangone.org To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.
Of 20 phase 1 interventional studies under Pre-Eclampsia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin